BiotechTube
Home/Pipeline/Personalized Medicine Assays (Patient-Derived Explants)

Personalized Medicine Assays (Patient-Derived Explants)

Oncology

Research-Use OnlyActive

Key Facts

Indication
Oncology
Phase
Research-Use Only
Status
Active
Company
Aurita Bioscience

About Aurita Bioscience

Aurita Bioscience is a private biotechnology company developing a disruptive 3D cell culture ecosystem designed to overcome the limitations of traditional 2D and hydrogel-based 3D models. Its core technologies—LLS® microgels and Darcy™ perfusion plates—create a tunable, physiologically relevant microenvironment that supports complex cellular interactions, prolonged viability, and high-fidelity in situ imaging. The company is actively engaged in collaborative research projects in oncology, infectious disease (including SARS-CoV-2), and immunotherapy (CAR-T), positioning itself as a critical enabler for more predictive drug discovery and development.

View full company profile

Therapeutic Areas

OncologyInfectious DiseaseImmunology

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
GBR 830Glenmark PharmaceuticalsPhase 1
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
LockBody Platform AssetsCentessa PharmaceuticalsPre-clinical
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Alymsys (bevacizumab-maly)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved